Saturday, October 31, 2026

Marathon Stock Plummets 15%: Investors React To Latest News

ViaNews Editorial Team

January 11, 2024

Marathon Stock Plummets 15%: Investors React To Latest News

(VIANEWS) - Marathon (NASDAQ: MARA) saw its stock prices fall sharply on Thursday, falling 15.68% to EUR21.61 at 12:23 EST after opening at EUR25.63 the day prior. This represents an 18.12% drop from its 52-week high of EUR31.30; furthermore this drop follows two consecutive sessions of losses which contributes to a negative trend during trading sessions. Furthermore, the NASDAQ index also fell 0.9% at EUR14,834.52, following four straight sessions of gains.

About Marathon

Marathon Digital Holdings, Inc. is an industry-leading digital asset technology company located in the United States. Specializing in mining digital assets with an eye towards blockchain ecosystem development, Marathon was founded in 2010 and established its headquarters in Fort Lauderdale, Florida in February 2021. Rebranding from Marathon Patent Group to Marathon Digital Holdings to highlight commitment to innovation and growth within digital asset industry

Yearly Analysis

Based on the provided data, Marathon's stock is currently underperforming its 52-week high while outpacing its 52-week low. Marathon is projected to experience sales growth this year of 204.9 % which may provide investors with some hope; however, such rates may not be sustainable over the long term. EBITDA at 17.65 indicates the company is making profits through operations which should give an indication of overall financial health of Marathon.

Technical Analysis

Marathon's stock is currently trading above both its 50-day and 200-day moving averages, signalling an upward trend both short- and long-term. Furthermore, Marathon's last reported volume of 139341117 significantly outstripped its usual trading activity indicating increased trading activity. Marathon's intraday variation average over the past week, month, and quarter has been negative 0.72%; positive 3.08%; and positive 5.70%, respectively. Marathon experienced its highest amplitude of average volatility last week (5.86%) 7.55% during its most volatile month (7) and quarter (5.70). According to the stochastic oscillator, Marathon's stock may be considered oversold (=20), suggesting it is undervalued and potentially due for a price rebound. Overall, Marathon's bullish trend and oversold conditions may signal potential for price gains over the short term; however, investors should conduct extensive research before making any definitive investment decisions.

Quarter Analysis

Based on available data, Marathon's sales growth for this quarter and next is 337% and 189% respectively. Furthermore, Marathon estimated its growth estimates for both quarters at 88.7% and 140%, respectively. Year-on-year quarterly revenue growth also saw significant gains at 671.1% with twelve trailing months showing revenue totalling 259.16M. Marathon's growth projections are promising, signaling great potential for investment. However, past performance does not guarantee future outcomes and investors should conduct further investigation before making their decisions.

Equity Analysis

Marathon has experienced an Earnings Per Share (EPS) loss for the trailing twelve months at EUR-3.08 per share. This indicates that they have experienced an overall net loss throughout the period. Marathon's Return on Equity (ROE) for the last twelve months stands at negative -42.13%, suggesting it has not generated sufficient profits to compensate shareholders adequately. Investors should take this into consideration before making investment decisions and may wish to look at other factors first before taking decisive actions.

More news about Marathon (MARA).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com